

INDOCO REMEDIES LIMITED

Regd. Office: Indoco House, 166, CST Road, Santacruz (E), Mumbai 400 098

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2009

				(Rs. In Lacs)
		Overter anded	0	Vooranded
	Particulars	Quarter ended	Quarter ended	Year ended
0.11.		30.06.2009	30.6.2008	31.03.2009
Sr.No		(Unaudited)	(Unaudited)	(Audited)
1 1/2	a) Salas and Income from Operations	9.925	11,090	35,526
	a) Sales and Income from Operations .ess : Excise Duty	9,925	141	462
	let Sales and Income from Operations	9,834	10,949	35,064
	b) Other Operating income	229	64	338
	otal	10,063	11,013	35,402
	Expenditure :	10,000	11,010	00,402
	(a) (Increase)/Decrease in Finished Goods Stock in			
	rade and work in progress	(270)	(355)	(513)
	(b) Consumption of raw materials	3,663	3,754	12,376
	(c) Purchase of traded goods	637	1,130	3,094
	(d) Employees cost	1,294	1,123	4,794
	(e) Depreciation	279	284	1,116
	(f) Research & Development Expenses	248	205	923
	(g) Other Expenditure	2,399	2,266	9,768
	(h) Total	8,250	8,407	31,558
	Profit from Operations before Interest and	0,200	0,407	01,000
	Exceptional Items	1,813	2,606	3,844
	Other Income	8	22	55
	Profit before Interest and Exceptional Items	1,821	2,628	3,899
	nterest	93	136	585
	Profit after Interest but before Exceptional Items	1,728	2,492	3,314
	Exceptional Items	.,.20	_,	-
	Profit from Ordinary Activities before tax	1.728	2,492	3.314
	Provision for Tax - Current	195	279	370
	- Deferred	40	38	108
	- Fringe Benefit Tax	-	25	93
	- Prior Year	_	(31)	(31)
	- MAT Credit	(195)	(279)	(370)
11 N	let Profit from Ordinary Activities after tax	1,688	2,460	3,144
	Extraordinary Items	-	_,	-
	let Profit for the period	1,688	2,460	3,144
	Paid up Equity Share Capital (Face value Rs.10/- each)	1,228.67	1228.67	1,228.67
	Reserves excluding Revaluation Reserves	-,	.220.01	26,615.61
	Earning Per Share (EPS) - Not Annualised - Rs.			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
	a) Basic and diluted EPS before Extraordinary Items	13.74	20.02	25.59
`	b) Basic and diluted EPS after Extraordinary Items	13.74	20.02	25.59
,	Public shareholding			
	- No of Shares	47,97,836	48,82,766	50,29,231
	- % of Shareholding	39.05	39.74	40.93
	Promoters and promoters group shareholding			
) Pledged/Encumbered			
	- Number of shares	8,200	-	8,200
	- Percentage of shares (as a % of the total	0.11	-	0.11
	shareholding of promoter and promoter group)	,,,,		
	- Percentage of shares (as a % of the total share	0.07	-	0.07
	capital of the company)			
b) Non-encumbered			
~	- Number of shares	74,80,678	_	72,49,283
	- Percentage of shares (as a % of the total	99.89	_	99.89
	shareholding of promoter and promoter group)	55.00		33.30
	- Percentage of shares (as a % of the total share	60.88	_	59.00
	capital of the company)			

Notes:

- The company has only one primary reportable segment of activity, namely, Pharmaceuticals.
- 2 The figures for the previous periods have been regrouped and reclassified, wherever necessary.
- 3 Summary of investor complaints: As on 01.04.2009: Nil, Received during quarter: 2, Resolved:2, Pending as on 30.06.2009: Nil.
- 4 The above results have been recommended by the Audit Committee and taken on record at the meeting of Board of Directors held on 30th July 2009 and have been subjected to a Limited Review by the Statutory Auditors of the Company.

By Order of the Board

Place : Mumbai Suresh G. Kare
Date : July 30, 2009 Chairman & Managing Director